Keros reported a net income of $148.5 million in the first quarter of 2025 as compared to a net loss of$43.1 million in the first quarter of 2024. The increase of $191.6 million was largely due to revenue recognized related to Keros' license agreement with Takeda Pharmaceuticals U.S.A., Inc., partially offset by increased research and development efforts as well as additional investments to support the achievement of Keros' clinical and corporate goals. Research and development expenses were$48.7 million ...